Cargando…

Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection

PURPOSE: To understand similarities and differences in patient treatment goals as selected by US psychiatrists, adult patients with schizophrenia, and their caregivers in a real-world setting in the United States, including stratification by current medication and age. PATIENTS AND METHODS: Data wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Fitzgerald, Heather M, Shepherd, Jason, Bailey, Hollie, Berry, Mia, Wright, Jack, Chen, Maxine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544790/
https://www.ncbi.nlm.nih.gov/pubmed/34707359
http://dx.doi.org/10.2147/NDT.S330936
_version_ 1784589891935404032
author Fitzgerald, Heather M
Shepherd, Jason
Bailey, Hollie
Berry, Mia
Wright, Jack
Chen, Maxine
author_facet Fitzgerald, Heather M
Shepherd, Jason
Bailey, Hollie
Berry, Mia
Wright, Jack
Chen, Maxine
author_sort Fitzgerald, Heather M
collection PubMed
description PURPOSE: To understand similarities and differences in patient treatment goals as selected by US psychiatrists, adult patients with schizophrenia, and their caregivers in a real-world setting in the United States, including stratification by current medication and age. PATIENTS AND METHODS: Data were drawn from the Adelphi Schizophrenia Disease Specific Programme™, a point-in-time survey of psychiatrists and their consulting adult patients with schizophrenia, conducted from June to October 2019. Psychiatrists completed record forms for their next 8 consecutive outpatients and (where possible) 2 inpatients matching inclusion criteria. Participating psychiatrists, patients, and caregivers completed treatment goal questionnaires as part of the survey. RESULTS: Psychiatrists (n = 124) provided data on 1204 patients with schizophrenia, including 1135 on drug treatment (207 inpatients [18%] and 928 outpatients [82%]); questionnaires were completed by 555 patients and 135 caregivers. Decrease in disease symptoms was identified as the most important patient treatment goal by patients (64%), psychiatrists (selecting for 63% of patients), and caregivers (selecting for 68% of patients). Patients, psychiatrists, and caregivers similarly rated the least important goals (less sexual problems and less weight gain). Patients indicated their current medication helped to reach their most important goals: decrease in disease symptoms (68%) and thinking more clearly (39%). Findings based on analysis of treatment goals by treatment and age were similar to overall trends. CONCLUSION: These findings, including identification of a primary consensus goal of decrease in disease symptoms, may help with discussions between patients with schizophrenia, psychiatrists, and caregivers to inform effective management strategies and encourage shared decision-making.
format Online
Article
Text
id pubmed-8544790
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-85447902021-10-26 Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection Fitzgerald, Heather M Shepherd, Jason Bailey, Hollie Berry, Mia Wright, Jack Chen, Maxine Neuropsychiatr Dis Treat Original Research PURPOSE: To understand similarities and differences in patient treatment goals as selected by US psychiatrists, adult patients with schizophrenia, and their caregivers in a real-world setting in the United States, including stratification by current medication and age. PATIENTS AND METHODS: Data were drawn from the Adelphi Schizophrenia Disease Specific Programme™, a point-in-time survey of psychiatrists and their consulting adult patients with schizophrenia, conducted from June to October 2019. Psychiatrists completed record forms for their next 8 consecutive outpatients and (where possible) 2 inpatients matching inclusion criteria. Participating psychiatrists, patients, and caregivers completed treatment goal questionnaires as part of the survey. RESULTS: Psychiatrists (n = 124) provided data on 1204 patients with schizophrenia, including 1135 on drug treatment (207 inpatients [18%] and 928 outpatients [82%]); questionnaires were completed by 555 patients and 135 caregivers. Decrease in disease symptoms was identified as the most important patient treatment goal by patients (64%), psychiatrists (selecting for 63% of patients), and caregivers (selecting for 68% of patients). Patients, psychiatrists, and caregivers similarly rated the least important goals (less sexual problems and less weight gain). Patients indicated their current medication helped to reach their most important goals: decrease in disease symptoms (68%) and thinking more clearly (39%). Findings based on analysis of treatment goals by treatment and age were similar to overall trends. CONCLUSION: These findings, including identification of a primary consensus goal of decrease in disease symptoms, may help with discussions between patients with schizophrenia, psychiatrists, and caregivers to inform effective management strategies and encourage shared decision-making. Dove 2021-10-21 /pmc/articles/PMC8544790/ /pubmed/34707359 http://dx.doi.org/10.2147/NDT.S330936 Text en © 2021 Fitzgerald et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Fitzgerald, Heather M
Shepherd, Jason
Bailey, Hollie
Berry, Mia
Wright, Jack
Chen, Maxine
Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
title Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
title_full Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
title_fullStr Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
title_full_unstemmed Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
title_short Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
title_sort treatment goals in schizophrenia: a real-world survey of patients, psychiatrists, and caregivers in the united states, with an analysis of current treatment (long-acting injectable vs oral antipsychotics) and goal selection
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544790/
https://www.ncbi.nlm.nih.gov/pubmed/34707359
http://dx.doi.org/10.2147/NDT.S330936
work_keys_str_mv AT fitzgeraldheatherm treatmentgoalsinschizophreniaarealworldsurveyofpatientspsychiatristsandcaregiversintheunitedstateswithananalysisofcurrenttreatmentlongactinginjectablevsoralantipsychoticsandgoalselection
AT shepherdjason treatmentgoalsinschizophreniaarealworldsurveyofpatientspsychiatristsandcaregiversintheunitedstateswithananalysisofcurrenttreatmentlongactinginjectablevsoralantipsychoticsandgoalselection
AT baileyhollie treatmentgoalsinschizophreniaarealworldsurveyofpatientspsychiatristsandcaregiversintheunitedstateswithananalysisofcurrenttreatmentlongactinginjectablevsoralantipsychoticsandgoalselection
AT berrymia treatmentgoalsinschizophreniaarealworldsurveyofpatientspsychiatristsandcaregiversintheunitedstateswithananalysisofcurrenttreatmentlongactinginjectablevsoralantipsychoticsandgoalselection
AT wrightjack treatmentgoalsinschizophreniaarealworldsurveyofpatientspsychiatristsandcaregiversintheunitedstateswithananalysisofcurrenttreatmentlongactinginjectablevsoralantipsychoticsandgoalselection
AT chenmaxine treatmentgoalsinschizophreniaarealworldsurveyofpatientspsychiatristsandcaregiversintheunitedstateswithananalysisofcurrenttreatmentlongactinginjectablevsoralantipsychoticsandgoalselection